Core Viewpoint - The company, Huaheng Biotechnology, is investing 3.9 billion RMB to advance AI-driven biomanufacturing, establishing a research and pilot demonstration base for artificial intelligence in biomanufacturing [1][2]. Investment Purpose - The investment aims to transition biomanufacturing from traditional fermentation to precision and intelligence, ensuring the company maintains its industry leadership and meets market demands for high-quality, low-cost products [5]. - By integrating advanced microbial fermentation technology with AI, the company seeks to achieve real-time monitoring and optimization of production processes, enhancing both yield and quality [5]. - The investment will help establish an intelligent production system, improving the company's core competitiveness through precise control of fermentation parameters and the creation of a proprietary database for protein design [5]. Project Overview - Project Name: AI Precision Fermentation and Protein Engineering Shared Demonstration Project [9]. - Investment Amount: 3.2 billion RMB [9]. - Location: Changfeng County, Shuangfeng Economic Development Zone [9]. - Project Area: 64 acres [9]. - Expected Construction Period: 36 months [9]. - Construction will include new production workshops, finished goods warehouses, tank areas, office buildings, R&D buildings, and comprehensive buildings [9].

Core Viewpoint - Shanghai Fengxian is developing into a key area for advanced manufacturing, cutting-edge technology transformation, talent innovation, and ecological urban integration, highlighted by the launch of the "Love Fengxian - 5.20 Talent Day" series of events [1][2] Group 1: Talent Development Initiatives - The establishment of "Talent Day" aims to demonstrate the district's commitment to attracting talent and accelerating the creation of a talent hub in southern Shanghai [1] - A total of 10 talent projects were signed, and various talent policies were promoted during the event, including the introduction of the "AI Xiaoxian" and "Xianlai Wuyou" talent service cards [1][2] Group 2: Financial and Spatial Support - Fengxian has set up a special development fund of 1 billion yuan for industry-education integration and is providing 100,000 square meters of quality space support for projects and high-end research platforms [2] - The district focuses on key concerns of talent, utilizing the "AI Xiaoxian" smart assistant to consolidate policies and services related to talent settlement, housing, employment, and innovation [2] Group 3: Future Development Plans - Future initiatives will focus on the construction of a returnee town and the optimization of the Bay University cluster, aiming to expand the talent project reservoir and cultivate new driving forces for industry-talent integration [2]

Core Viewpoint - Chinese enterprises are undergoing a critical transformation from a "manufacturing power" to an "innovation powerhouse" amid global supply chain restructuring and intensified technological competition [1] Group 1: Patent as a Strategic Armor - Chinese companies face dual pressures: the trend of "decentralization" in global supply chains and the shift from cost competition to value competition in the domestic market [2] - The "14th Five-Year Plan" emphasizes the need to build a strong intellectual property (IP) nation, highlighting the importance of IP protection for innovation-driven development [2] - According to the World Intellectual Property Organization (WIPO), China has maintained the highest number of invention patent applications globally for 12 consecutive years, but the number of patent infringement cases is also increasing [2] Group 2: Systemic Harm from Weak Patent Protection - Weak patent protection leads to systemic harm for enterprises and industries, resulting in market imitation that can significantly reduce sales and dampen R&D enthusiasm [3] - The phenomenon of "bad money driving out good" has previously caused several domestic sectors, such as solar energy and lithium batteries, to fall into "low-end involution" due to price wars stemming from inadequate patent protection [3] Group 3: The Case of Huaheng Biological - The ongoing patent infringement case involving Huaheng Biological and Huairui Biological is a significant example of IP protection in the biomanufacturing industry [4] - Huaheng Biological is the first global company to produce β-alanine using fermentation and enzyme engineering technology, with a core patent that enhances production efficiency and product competitiveness [4] - The patent in question is valid until 2037 and is crucial for the industry's innovation ecosystem; if infringement continues, it may lead to widespread imitation and damage the sector [5] Group 4: Strategic Upgrades in IP Protection - Huaheng Biological's proactive approach to IP protection includes independent R&D, patent portfolio development, and regular IP audits to identify infringement [6] - The transition from "passive defense" to "active shaping of the competitive environment" reflects a strategic upgrade in IP management [6] - In the era where "patents are king," the ability to build a "patent firewall" is essential for Chinese enterprises to navigate high-quality development and overcome bottlenecks in the global value chain [6]

Core Viewpoint - SiPeng Technology has successfully completed a multi-million Pre-A+ round of financing, which will be used to accelerate the commercialization of bio-based materials and the construction of a third-generation carbon source bio-manufacturing platform [1][2]. Group 1: Company Overview - SiPeng Technology, established in 2022, focuses on material synthesis and bio-manufacturing, with a founding team that has over 20 years of industry experience [1]. - The company has achieved significant breakthroughs in "bottleneck" technologies and has successfully scaled up multiple bio-manufacturing products [1][2]. - SiPeng Technology is recognized as a representative enterprise for the transformation of scientific achievements from Shanghai Jiao Tong University [1]. Group 2: Financing and Investment - The recent Pre-A+ round was led by Shanghai Guotou Futeng Capital, with XiQiao Capital serving as the exclusive financial advisor [1]. - In October 2024, SiPeng Technology completed a nearly 100 million Pre-A round, which was led by Guotou Chuanghe and followed by Rugao Kechuang Investment [1]. Group 3: Technological Advancements - SiPeng Technology has developed a smart bio-manufacturing platform and a high-performance material application development platform, aiming to produce globally competitive bio-based products [1][2]. - The company has broken the overseas technology monopoly and has completed mass production verification of various bio-based polyols/acids, achieving international leadership in fermentation concentration and cost [1][2]. Group 4: Carbon Source Utilization - SiPeng Technology is collaborating with the Tianjin Institute of Industrial Biotechnology of the Chinese Academy of Sciences to promote the industrialization of bio-based material monomers using methanol as a raw material [2]. - The company is focusing on the industrialization of first and second-generation carbon source products while planning to utilize methanol and carbon dioxide as raw materials for third-generation carbon sources, significantly reducing the reliance on food carbon sources and lowering bio-manufacturing costs [2]. Group 5: Market Outlook - Shanghai Guotou Futeng Capital emphasizes that the synthetic biology field requires both product development and scalable sales for long-term success, aligning with the goals of carbon neutrality and sustainability [4]. - SiPeng Technology aims to establish a long-term market advantage through strain iteration, carbon source replacement, and continuous optimization of production processes [4].

Core Viewpoint - Synthetic biology and biomanufacturing are gaining significant attention and support from various sectors, including government, academia, and industry, highlighting their potential as new productive forces in the economy [1][15]. Group 1: Event Overview - The SynBio China Third China Synthetic Biology "Scientists + Entrepreneurs + Investors" Expo will be held on August 1-2, 2025, at the Suzhou International Expo Center [3]. - The expo will feature seven sub-conferences, including discussions on synthetic biology applications in food health, protein biomanufacturing, and innovative skincare [3][4]. Group 2: Industry Trends - Synthetic biology is seen as a key to understanding life and a disruptive technology that can accelerate China's transition from a large to a strong biological economy [15]. - The industry faces challenges such as achieving large-scale production, realizing the value of synthetic biological products, and innovating core competitiveness [15]. Group 3: Applications and Innovations - Innovations driven by synthetic biology include the development of next-generation food additives, personalized health foods, and sustainable protein sources [9][12]. - The application of synthetic biology in cosmetics is also notable, with advancements in recombinant collagen and bioactive ingredients for skincare [13][16]. Group 4: Collaboration and Networking - The event aims to facilitate collaboration among innovators, industry experts, and investors, providing a platform for project promotion and industry guidance [18]. - Various types of projects are encouraged to participate, including startups and application-oriented enterprises in synthetic biology [22].

湖北首鼎创始人桑涛博士是武汉东湖高新区首批产业领军人才，在武汉国家生物产业基地设立研发中心，在全球率先探 索建立以芦苇及农作物秸秆为原料的合成生物制造产业，生产生物树脂、生物塑料等先进环保新材料，获得50多项发明 专利。 湖北首鼎还从芦苇中提取高活性酶解木质素合成生物树脂，用于制造碳纤维复合材料，可应用于航空航天、轨道交通、 新能源等高端制造领域。目前全球碳纤维复合材料需求迅速增长，国产环氧树脂韧性不足，很多高端产品都从国外进 口。该公司研发的生物树脂可解决"卡脖子"问题，具有强大市场竞争力，得到行业高度认可。 日前从湖北首鼎实业有限公司获悉，全球首条以芦苇为原料的可降解生物塑料生产线在石首投产。这项自主研发的生产 技术国际领先，填补了非粮生物塑料制造领域的空白。 负责技术研发的上海汉禾生物新材料科技有限公司工程师刘畅介绍，传统塑料生产以石油为原料，不能降解，造成环境 污染，甚至危害人类健康；可降解生物塑料以玉米等粮食淀粉为原料，成本高，产品贵，应用受到限制。上海汉禾控股 的湖北首鼎生产的秸秆生物塑料，售价比粮食塑料显著降低，规模化生产后将比石化塑料价格更便宜，可完全降解为二 氧化碳和水，能有效解决白色污染难 ...

Core Viewpoint - The company plans to invest 320 million yuan in an "AI-driven precision fermentation and protein engineering shared demonstration project" to maintain its industry leadership and meet market demand for high-quality, low-cost products [1][2]. Investment Details - The company signed an investment agreement worth 390 million yuan with the Anhui Changfeng (Shuangfeng) Economic Development Zone Management Committee for the construction of an AI-driven bio-manufacturing R&D and pilot demonstration base [1]. - The total investment agreements signed with the Anhui Changfeng (Shuangfeng) Economic Development Zone in the past 12 months amount to 710 million yuan, meeting the disclosure standards of the Sci-Tech Innovation Board [1]. Project Specifications - The project will include the construction of new production workshops, finished product warehouses, tank areas, office buildings, R&D buildings, and comprehensive buildings, with an estimated construction period of 36 months [2]. - Funding for the project will come from the company's own or self-raised funds [2]. Company Overview - The company focuses on synthetic biology technology and is engaged in the R&D, production, and sales of bio-based products, including amino acids, vitamins, and bio-based new material monomers [2]. - In 2024, the company achieved a revenue of 2.178 billion yuan, a year-on-year increase of 12.37%, and a net profit of 190 million yuan [2]. Technological Advancements - The company utilizes gene synthesis, gene editing, pathway assembly and optimization, and global cell optimization technologies to create new cell factories, accelerating the industrialization of scientific achievements [3]. - The development of AI technology is expected to enhance gene editing efficiency, metabolic pathway optimization, production process optimization, and protein design, further empowering breakthroughs in biosynthesis technology [3][4]. Production Innovation - The company aims to adopt advanced microbial fermentation technology combined with AI for precise control of the fermentation process, introducing automation equipment and control systems for real-time monitoring and optimization of production [4]. - The investment will help the company build an intelligent production system, enhancing its core competitiveness [4].

Core Viewpoint - Anhui Huaheng Biological Technology Co., Ltd. plans to invest RMB 320 million in the construction of an "Artificial Intelligence Precision Fermentation and Protein Engineering Shared Demonstration Project" to maintain its industry leadership and meet market demand for high-quality, low-cost products [1][2]. Investment Overview - The investment amount for the project is RMB 320 million, primarily funded by self-owned or self-raised funds, with a construction period of 36 months [1][2]. - The project is located in the northeast corner of the intersection of Shuangfeng Road and Yingzhou Road in the Shuangfeng Economic Development Zone, Changfeng County [1]. Decision and Approval Process - The investment decision was approved by the company's management and does not require board approval, as it falls within the management's authority [1][2]. - The company has signed a total of RMB 710 million in investment agreements with the Changfeng (Shuangfeng) Economic Development Zone Management Committee over the past 12 months [2]. Project Details - The project aims to utilize advanced microbial fermentation technology combined with artificial intelligence for precise control of the fermentation process, enhancing production efficiency and product quality [5]. - The project will establish a smart production system, improving the company's core competitiveness in the market [5]. Environmental and Safety Compliance - The company is required to adhere to national environmental protection standards and energy-saving regulations during the construction and operation of the project [4]. - The project must comply with safety management laws and regulations, ensuring proper handling of wastewater, waste gas, and solid waste [4].

融行业智慧、共襄盛举 作为新质生产力的代表，合成生物学、生物制造以及生物产业，近些年，受到来自政产学研用金 各方广泛关注和重点支持，多地政府将合成生物制造产业写进工作报告。 科学家、企业家和投 资家，在产业发展中发挥着重要作用。 聚产业力量、擘画未来 SynBio China第三届中国合成生物学"科学家+企业家+投资家"博览会 将于2025年8月1-2日在 苏州国际博览中心B馆 举办（同期举办 第七届CMC-China博览会 ）！ 本次博览会共包含7个子会议： 展会名称： Synbio China 第三届中国合成生物学"科学家+企业家+投资家"博览会 第三届中国合成生物学"科学家+企业家+投资家"大会 SynBio China合成生物学与食品大健康产业大会 中国蛋白生物制造大会 美之原·合成生物学功能护肤大会 美之注·注射医疗美容产业大会 SynBio China合成生物学产学研对接会 SynBio China合成生物学新锐项目路演 诚邀莅临，共襄盛举 展会 时间： 2025年8月1-2日 展会 地点： 苏州国际博览中心·B馆 展会 规模： 20000+ 主办单位： synbio深波 支持单位： Synbio ...

2025.05. 19 本文字数：2378，阅读时长大约4分钟 作者 | 第一财经 祝嫣然 2025年是国有企业改革深化提升行动的收官之年，也是新一轮改革的谋划之年。 国务院国资委全面深化改革领导小组日前召开2025年第一次全体会议，听取高质量完成国有企业改 革深化提升行动重点难点任务落实情况，研究进一步深化国资国企改革的方案。 会议明确，要高起点谋划好下一步深化国资国企改革工作，突出解决制约国有企业高质量发展的深层 次体制机制难题，构建与新质生产力更相适应的生产关系，推动国有资本和国有企业做强做优做大， 增强核心功能、提升核心竞争力，更好履行战略使命。 更大力度推进产业焕新 2023年启动实施的国企改革深化提升行动取得积极进展。会议指出，功能使命类任务加快落地，关 键核心技术攻关实现新突破，产业焕新行动、未来产业启航行动深入实施，传统产业转型升级持续加 速，重点领域重组整合扎实推进，"三个作用"充分发挥。 此外，体制机制类任务巩固深化，中国特色现代企业制度进一步完善，三项制度改革深入推进，"一 业一策、一企一策"考核全面实施，穿透式监管进一步强化，监管效能明显提高，有效激发企业内生 活力动力。 去年中央企业 ...